{"name":"Artu Biologicals","slug":"artu-biologicals","ticker":"","exchange":"","domain":"","description":"Artu Biologicals is a biotechnology company focused on developing and commercializing innovative allergen immunotherapy products. The company has two marketed drugs, Oralgen and grass pollen extract, which are used in the treatment of allergies. Despite limited public financial data, Artu Biologicals continues to advance its pipeline and maintain a presence in the allergy treatment market.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Oralgen","genericName":"Oralgen","slug":"oralgen","indication":"Other","status":"marketed"},{"name":"grass pollen extract","genericName":"grass pollen extract","slug":"grass-pollen-extract","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Oralgen","genericName":"Oralgen","slug":"oralgen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"grass pollen extract","genericName":"grass pollen extract","slug":"grass-pollen-extract","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQa0dtZmVmbTFNak42OUJhblQzSUliQld2SENsUy12ZUdjZmRPWGFOZk8zT0cydE1sckpSRHYyOWtNQnU2Qk9mNXZRV0lFdzgySENQVnJsWk1IRThqd05uY1g1UFNnWGlRbFhJMkNxN0ItUzFUcXNJWnR4ZktxYTBsWFhuX0Fia3NHRF9YYVZnaw?oc=5","date":"2023-09-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany - Pharmaceutical Technology","headline":"Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQLXVzS1ljTW9wMHl2bDc2WWVFYi1OTzFRYzlVTnpSWlNta3JhMVllSVhJVU5LV3I4S1htU25hLUtBSjdwNlVURU9ESXB4OTVpWTdmTGFsZjZ6VUVDZzVTZ185dzJFck5PekJ5RkVLSHpUUjBhZXNZZWdnQ1hIVW84TjBZSDU3TnR0b1BKUmk5UHlWdjNWSzE0ZGR6ZF8?oc=5","date":"2021-07-19","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Pfizer sells Chinese copy biologicals plant to WuXi Biologics - Generics and Biosimilars Initiative","headline":"Pfizer sells Chinese copy biologicals plant to WuXi Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQQWQ5T0RsTERUSl9NMUhBWE9BdkVQeFVUOXBwN2ZpYndyZmJnQTFzTGxHME9VRmNMenYyZXdEcUVhWk9YcDVjcHo2RS0tb0lyaDRMVVRpRm1zMUdwVHVPZHBxSTdwUFdJWElMZ0lFalJtcDlzWFFxVVpDY21zYXUzX3FXWjBsOW1IaTZzNUh3cnZRM0xjTEJHZVFKSFpIcGZSRm5ZbEV4eEVySmdYckZz?oc=5","date":"2021-07-04","type":"patent","source":"Generics and Biosimilars Initiative","summary":"WuXi Biologics expands its biologicals manufacturing facilities - Generics and Biosimilars Initiative","headline":"WuXi Biologics expands its biologicals manufacturing facilities","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}